Table 1.
The clinical and laboratory characteristics of PHNET and NBNC-HCC in the study.
| Variable | PHNET (n=14) | NBNC-HCC (n=28) | P value |
|---|---|---|---|
| Age (range, year) | 56.9 ± 12.2 (32-74) | 58.5± 10.4 (40-78) | 0.984 |
| Sex | 0.040 | ||
| Male | 6 (42.9%) | 21 (75.0%) | |
| Female | 8 (57.1%) | 7 (25.0%) | |
| Chronic hepatitis B | 2 (14.3%) | 0 (0.0%) | 0.106 |
| Chronic hepatitis C | 0 (0.0%) | 0 (0.0%) | — |
| Fatty liver disease | 1 (7.1%) | 6 (21.4%) | 0.242 |
| AFP (ng/ml) | 0.111 | ||
| ≤ 20 | 13 (92.9%) | 20 (71.4%) | |
| > 20 | 1 (7.1%) | 8 (28.6%) | |
| CA 19-9 (U/ml) | 0.350 | ||
| ≤ 30 | 11 (78.6%) | 25 (89.3%) | |
| > 30 | 3 (21.4%) | 3 (10.7%) | |
| CEA (ng/ml) | 0.457 | ||
| ≤ 5 | 12 (85.7%) | 26 (92.9%) | |
| > 5 | 2 (14.3%) | 2 (7.1%) | |
| ALT (IU/L) | 0.798 | ||
| ≤ 40 | 11 (78.6%) | 21 (75.0%) | |
| > 40 | 3 (21.4%) | 7 (25.0%) | |
| Total bilirubin (umol/L) | 0.500 | ||
| ≤ 28 | 13 (92.9%) | 24 (85.7%) | |
| > 28 | 1 (7.1%) | 4 (14.3%) | |
| Albumin (g/L) | 0.545 | ||
| ≤ 40 | 0 (0.0%) | 2 (7.1%) | |
| > 40 | 14 (100.0%) | 26 (92.9%) |
PHNET, primary hepatic neuroendocrine tumors. NBNC-HCC, hepatocellular carcinoma with negative for hepatitis B virus surface antigen and hepatitis C antibody; AFP, alpha-fetoprotein; CA 19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen. Unless otherwise stated, data are numbers of patients, with percentage in parentheses.